Latest Southeast Asia News

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Me Today Limited delivered a 36% revenue surge to $7.96 million in FY26, cutting its EBITDA loss by 43% and locking in $1.59 million of new capital from major shareholders ahead of October warrant exercises.

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

ParagonCare’s FY26 results show modest revenue and underlying earnings growth, overshadowed by a large credit loss provision related to the Infinity Pharmacy Group debt.

Monvia Limited reported a $28.7 million revenue year with a $6.9 million adjusted EBITDA, exceeding IPO forecasts, while renewing a $60 million contract with MetLife and completing its ASX listing.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

SportsHero Limited has partnered with Carry1st to distribute gaming top-up vouchers and ePINs via its HeroPlay platform, adding major titles and platform vouchers to its Southeast Asian offering.

Ovanti Limited has announced a complete global exit from the Buy Now Pay Later sector, ceasing all BNPL activities and shifting its focus to its established iSentric business in Southeast Asia, alongside significant cost reductions and imminent legal action against its former US BNPL CEO.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Noumi Limited lifted FY26 revenue by 8.8% and adjusted operating EBITDA by 7.6%, driven by Dairy & Nutritionals' strong earnings and strategic investments in Plant-based Milks. The company faces refinancing uncertainty with $610 million convertible notes maturing in May 2027, prompting a proposed acquisition by majority shareholder Arrovest.

Bega Cheese Limited has delivered a robust FY2026 with a $54.8 million statutory profit, a 6.7% revenue increase, and a raised final dividend of 7.5 cents per share. The company is advancing its strategic growth plans focused on high-protein products, international expansion, and sustainability initiatives.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.